Senescence-Associated Secretory Phenotypes Reveal Cell-Nonautonomous Functions of Oncogenic RAS and the p53 Tumor Suppressor
Open accessThe DOI matches its Crossref record; 82 of the 82 references it cites were found in a registry or an index; 25 of the 72 sources its claims cite were checked for support.
Abstract
Cellular senescence suppresses cancer by arresting cell proliferation, essentially permanently, in response to oncogenic stimuli, including genotoxic stress. We modified the use of antibody arrays to provide a quantitative assessment of factors secreted by senescent cells. We show that human cells induced to senesce by genotoxic stress secrete myriad factors associated with inflammation and malignancy. This senescence-associated secretory phenotype (SASP) developed slowly over several days and only after DNA damage of sufficient magnitude to induce senescence. Remarkably similar SASPs developed in normal fibroblasts, normal epithelial cells, and epithelial tumor cells after genotoxic stress in culture, and in epithelial tumor cells in vivo after treatment of prostate cancer patients with DNA-damaging chemotherapy. In cultured premalignant epithelial cells, SASPs induced an epithelial-mesenchyme transition and invasiveness, hallmarks of malignancy, by a paracrine mechanism that depended largely on the SASP factors interleukin (IL)-6 and IL-8. Strikingly, two manipulations markedly amplified, and accelerated development of, the SASPs: oncogenic RAS expression, which causes genotoxic stress and senescence in normal cells, and functional loss of the p53 tumor suppressor protein. Both loss of p53 and gain of oncogenic RAS also exacerbated the promalignant paracrine activities of the SASPs. Our findings define a central feature of genotoxic stress-induced senescence. Moreover, they suggest a cell-nonautonomous mechanism by which p53 can restrain, and oncogenic RAS can promote, the development of age-related cancer by altering the tissue microenvironment.
Overview
CoChat Summary
TL;DR
Senescent human fibroblasts and epithelial cells develop a complex senescence-associated secretory phenotype (SASP) that can promote malignant phenotypes in neighboring cells, including epithelial–mesenchymal transition (EMT) and invasion. Oncogenic RAS and loss of p53 amplify and accelerate this SASP, suggesting p53 acts as a cell-nonautonomous tumor suppressor by restraining protumorigenic secreted factors.
Key findings
- Of 120 proteins assayed, 41 were significantly oversecreted by senescent cells compared with presenescent cells, while 79 showed no significant difference; the SASP included inflammatory cytokines/chemokines, growth factors, shed surface molecules, and survival factors.
- The SASP was conserved across cell types: normal fibroblasts and normal prostate epithelial cells overlapped significantly (p ≈ 10⁻³; r = 0.53; >66% overlap), and 24 proteins were shared between all fibroblast and all epithelial SASPs (p ≈ 10⁻⁵).
- SASP induction required genotoxic stress sufficient to cause senescence: 10 Gy X-irradiation induced a SASP, whereas 0.5 Gy did not; the SASP developed slowly, requiring 4–7 d after irradiation.
- Oncogenic RAS induced an amplified SASP: correlations with REP/XRA SASPs were 0.75 for WI-38/IMR-90 and 0.84 for HCA-2 fibroblasts; nine proteins were significantly more secreted in SEN(RAS) versus SEN(REP;XRA) across all fibroblasts, plus five RAS-unique proteins.
- p53 loss was not required to initiate or maintain a SASP, but it amplified it: a subset of SASP proteins was secreted at 5- to 30-fold higher levels after p53 inactivation, and combined p53 loss plus oncogenic RAS produced the most amplified SASP, with accelerated development within 2–4 d.
- SASP factors induced EMT and invasion in nonaggressive breast cancer cells; IL-6 and IL-8 blocking antibodies reduced SEN CM–stimulated invasion.
- In human prostate cancer biopsies after mitoxantrone chemotherapy, tumors showed higher p16INK4a and p21 mRNAs, lower cyclin A, MCM-3, and PCNA mRNAs, and higher mRNAs for IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β, while IL-2 mRNA did not significantly change.
Methods
- Human fibroblast strains (WI-38, IMR-90, BJ, HCA2, hBF184), normal prostate epithelial cells (PrECs), and prostate tumor lines (BPH1, RWPE1, PC3) were induced to senesce by replicative exhaustion (REP), 10 Gy X-irradiation (XRA), oncogenic RAS, or mitoxantrone (MIT); p53 was inactivated using GSE22 or shRNA.
- Conditioned media were analyzed with modified antibody arrays detecting 120 proteins, using ³⁵S-streptavidin detection for improved dynamic range; findings were validated by ELISA, immunostaining, invasion assays, and RT-PCR.
- Human prostate cancer biopsies were obtained before and after MIT chemotherapy; approximately 1,000 tumor epithelial cells were laser-captured per sample, and mRNA was quantified by RT-PCR. Statistical analyses used Pearson correlation, two-tailed Student t-test, and hypergeometric distribution for SASP overlap.
Limitations
- The paper does not include a formal limitations section.
- Evident from the text: the in vivo human SASP evidence relies on mRNA from laser-captured tumor cells rather than direct measurement of secreted proteins, with approximately 1,000 cells captured per sample.
- Evident from the text: many mechanistic conclusions come from cultured cells, and the SASP is described as not a fixed phenotype, with quantitative and qualitative differences among cell strains, tissues, and donors.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


![Figure 3 Chemotherapy-Induced SASP in Culture and In Vivo (A) Overall correlation between XRA and mitoxantrone (MIT)-induced SASPs for all three prostate epithelial cancer cell lines (BPH-1, RWPE-1, and PC-3). Correlations for the individual cell lines are given in the table to the right. The senescence inducer (XRA or MIT) is given in parentheses. (B–E) Human tumor cells were isolated from biopsies obtained from the same patient before MIT chemotherapy and from prostate tissue following prostatectomy after MIT chemotherapy. Laser captured cells were analyzed by quantitative RT-PCR for the mRNAs encoding the indicated proteins, as described in Materials and Methods and Text S1. The results are displayed on a log10 scale indicating the values before (horizontal or x-axis) compared to after (vertical or y-axis) chemotherapy (top left panel in [B]). Each black dot in (B, C, and D) represents the results obtained from a single patient. The average values for all patients before versus after chemotherapy are indicated by a red dot (B–D); these values are also represented as a heat map in (E). (B) Values for mRNAs encoding proteins associated with senescence (p16 and p21) and proliferation (cyclin A, MCM-3, and PCNA). (C) Values for mRNAs encoding SASP-associated proteins (IL-6, IL-8, GM-CSF, GRO-α, IGFBP-2, and IL-1β). (D) Value for an mRNA encoding a non-SASP–associated protein (IL-2). (E) Averages for the values shown in (B–D). Overall p-values, determined by the Student t-test, and number of paired samples (or patients) analyzed for each mRNA are given to the right of the heat map. Signals higher than the prechemotherapy baseline are shown in red; signals below baseline are displayed in green.](https://figures.cochat.ai/paper-figures/92013b1ef9b3492d8c26b76b40577c28/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-3.jpg)


![Figure 6 p53 Restrains the SASP (A) CM containing factors secreted by the indicted cells were analyzed by antibody arrays and displayed, using PRE CM as the baseline. We pooled data from cells of the same genotype (p53 wild type or p53 deficient) under the same culture conditions. SEN indicates pooled data from cells originating from the same tissue (WI-38, IMR-90 from embryonic lung; and HCA-2, BJ from neonatal foreskin) and induced to senesce by REP or XRA. Pooling and averaging of highly correlated samples was performed as described for Figure 5, and details of the data processing are provided in Datasets S13–S16. The top four rows are the same top four rows in Figure 5A and are included to serve as a visual reference. The senescence inducer is given in parentheses. p53 status is indicated as either wild type (wt) or deficient (d) owing to either GSE22 expression or expression of an shRNA against p53. Manipulations are indicated in sequence, separated by a greater than symbol (>). The heat map key (right) indicates the log2-fold changes. Signals higher than the baseline are shown in yellow; signals below baseline are displayed in blue. Comparison between rows is accurately illustrated in (B) and (C) in which each genetically manipulated cell type is compared to its appropriate control baseline. (B) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from SEN cells made p53 deficient by GSE22, using untreated wild-type SEN values as the baseline. Green indicates WI-38 cells made senescent by XRA, after which p53 was subsequently inactivated by expressing GSE22 using a lentivirus; these cells do not resume proliferation (“unreverted”) upon p53 inactivation (see Figure S6). Blue indicates WI-38 in which p16 was inactivated by an shRNA, induced to senesce by XRA, then infected with the GSE22-expressing lentivirus; these cells do revert (REV) after p53 inactivation. Pink indicates HCA2 cells made SEN by XRA, then infected with GSE22 lentivirus; these cells also revert after p53 inactivation. (C) Log2-fold values for SASP factors that are significantly increased, or significantly and uniquely (as indicated by double asterisks [**]) elevated, in CM from cells made p53-deficient (by GSE22 expression), then induced to senesce by REP, XRA, or RAS. Red indicates WI-38 and IMR90 (averaged) cells expressing GSE22, then induced to senesce by XRA or REP, using cells made SEN by XRA or REP as a baseline. Gray indicates WI-38, IMR-90, and HCA2 (averaged) expressing GSE22, then made senescent by RAS, using SEN by RAS as a baseline. (D) WI-38 cells expressing GSE22 were induced to senesce by XRA and then immunostained for the SASP proteins IL-6 and IL-8, the senescence marker p16INK4a, and p53, which accumulates in the presence of GSE22. (E) Comparative graphical representation of the secretory profiles of cells made senescent by XRA or REP (dotted line), RAS (black line), p53 inactivation (GSE22) followed by XRA or REP (blue line), or p53 inactivation (GSE22) followed by RAS (red line). The increased slopes (as indicated by the arrow)indicate amplified SASPs. (F) Hierarchical cluster analysis of all the cells analyzed in (A), plus the SASP induced by RAS (see Figure 5). RAS status is indicated as either wild type (wt) or oncogenic (o) owing to expression of Ha-RASv12. (G) WI-38 cells with wild-type (wt) or inactive (GSE) p53 were irradiated or induced to express oncogenic RAS (RAS), and CM was collected 4 or 10 d later. Soluble factors were analyzed by antibody arrays and displayed as described in Figure 1D, using PRE CM as the baseline (black column on the left; see also Figure S5C for details). Signals higher than baseline are shown in yellow; signals below baseline are in blue. n/a, not applicable. (H) Log2-fold values for prostate epithelial cell SASP factors that are significantly or uniquely (as indicated by double asterisks [**]) elevated in CM from p53-deficient cancer cells (PC3, BPH1, and RWPE1) that were induced to senesce by XRA, compared to primary p53 wild-type cells (PrECs) that were induced to senesce by XRA.](https://figures.cochat.ai/paper-figures/ec6066e9173e4732bc7f9d2c5718a2dd/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-6.jpg)
![Figure 7 Biological Activities of the Amplified SASP (A) T47D and ZR75.1 cells were incubated with the indicated CM for 3 d and then analyzed for cell scattering, immunostained for the indicated proteins, and analyzed for vimentin and actin levels by western blotting. Controls for the immunofluorescence from the same individual experiment are shown in Figure 4B. The senescence inducer is given in parentheses. p53 status was either wild type or deficient (GSE). Manipulations are indicated in sequence, separated by >. (B) Epithelial cells were incubated with CM from the indicated WI-38 cells and assayed for invasion as described in Materials and Methods and Figure 3C. Double asterisks (**) indicate p < 0.02. Error bars indicate the standard deviation around the mean. (C) Epithelial cells were incubated with CM from the indicated fibroblasts and cell number was determined by cell counting, total protein, or green fluorescent protein (GFP) fluorescence using epithelial cells expressing GFP, as described in [80]. A single asterisks (*) indicates p < 0.05. Error bars indicate the standard deviation around the mean. (D) Model for the cell-nonautonomous activities of oncogenic RAS and the p53 tumor suppressor protein. Oncogenic and genotoxic stress of sufficient magnitude to cause senescence induce a SASP, whereby cells secrete inflammatory cytokines, chemokines, and growth factors that can alter the tissue microenvironment and stimulate malignant phenotypes in nearby cells. Thus, in addition to their well-known cell-autonomous effects, oncogenes can promote cancer cell-nonautonomously by inducing a SASP. Oncogenic and genotoxic stress also activate p53, which suppresses cancer by cell-autonomous mechanisms (promoting repair, or inducing apoptosis or senescence). In addition, p53 suppresses cancer by the cell-nonautonomous effects of suppressing the intensity of the SASP and its deleterious effects.](https://figures.cochat.ai/paper-figures/c8eed762510f438c8789f2db0ec751a6/senescence-associated-secretory-phenotypes-reveal-cell-nonautonomous-functions-figure-7.jpg)
Verification
Claims the paper makes
19 Valid · 4 Not valid · 9 Not checked · 117 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Lastly, in mice and humans, a senescence response to strong mitogenic signals, such as those delivered by certain oncogenes, prevents premalignant lesions from progressing to malignant cancers [ 16 – 19 ].”
What the sources say
- Not checked — no full text of the sourcecites [16] Collado, 2005, Nature source
- Partly supportedcites [17] Chen, 2005, Nature sourceExperimental — accuracy not yet measured
The Abstract reports that p53-dependent senescence restricts Pten-deficient tumorigenesis in mice, and the human-specimen passage reports senescence staining mainly in prostate hyperplasia or PIN rather than frank tumour (page numbers unavailable). The human observations do not establish that senescence prevents progression, and the experimental finding concerns Pten loss rather than strong mitogenic signals generally. (LLM, conf=0.86)
- Partly supportedcites [18] Michaloglou, 2005, Nature sourceExperimental — accuracy not yet measured
The discussion (Nature, vol. 436, 4 August 2005; page not provided) says the findings support oncogene-induced senescence as a mechanism in humans that limits progression of premalignant lesions. The paper studies human melanocytes and naevi, not mice, and describes limitation of progression rather than categorical prevention. (LLM, conf=0.88)
- Not matchedcites [19] Braig, 2005, Nature
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Consistent with this view, senescent cells increase with age in mammalian tissues [ 27 ]”
What the sources say
- Supportedcites [27] Campisi, 2005, Cell source
The “Cellular Senescence and Aging” passage (page not provided) says that cells with characteristics of senescence accumulate with age in multiple tissues from humans and rodents. This supports the claim about mammalian tissues. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Senescent cells acquire many changes in gene expression, mostly documented as altered mRNA abundance, including increased expression of secreted proteins [ 33 – 41 ].”
What the sources say
- Partly supportedcites [33] Zhang, 2003, Proc Natl Acad Sci U S A sourceExperimental — accuracy not yet measured
The Results report hundreds of changes in transcript abundance during senescence in human fibroblasts, supporting the claim about altered gene expression measured as mRNA. They identify up-regulated genes encoding membrane-associated proteins, but the passages in our copy do not establish increased expression of secreted proteins; membrane-associated is not the same as secreted. (LLM, conf=0.85)
- Supportedcites [34] Chang, 2002, Proc Natl Acad Sci U S A source
The Results and Discussion report many gene-expression changes in senescent HCT116 cells, measured primarily with RNA-based methods, and specifically identify increased expression of genes for secreted factors. The paper also notes parallels with senescence in normal cells. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [35] Bavik, 2006, Cancer Res source
- Not checked — no full text of the sourcecites [36] Mason, 2004, Oncogene source
- Not checked — no full text of the sourcecites [37] Wajapeyee, 2008, Cell source
- Not matchedcites [38] Kortlever, 2006, Nat Cell Biol
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
- Not checked — no full text of the sourcecites [39] Parrinello, 2005, J Cell Sci source
- Supportedcites [40] Kuilman, 2008, Cell source
The Results (page not provided) report genome-wide expression analysis showing multiple gene classes upregulated during oncogene-induced senescence, including cytokine and chemokine genes. They also report increased IL-6 and IL-8 expression and secretion of IL-6 by senescent cells, supporting the claim about secreted proteins. (LLM, conf=0.91)
- Supportedcites [41] Acosta, 2008, Cell source
The Discussion (page unavailable) identifies increased production of various secreted proteins as a characteristic of senescent cells. It also reports that CXCR2 and many of its ligands are upregulated during senescence, supporting the claim about changes in expression. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Thus, oncogenes such as RAS, which are known to activate protumorigenic paracrine mechanisms during transformation [ 59 – 61 ], might also exert cell-nonautonomous protumorigenic effects through nontransformed cells during the process of inducing senescence ( Figure 7 D).”
What the sources say
- Supportedcites [59] Ancrile, 2007, Genes Dev source
The citation supports the sentence’s background clause about protumorigenic paracrine mechanisms during RAS-driven transformation. The Abstract says RAS-induced IL6 acts in a paracrine fashion to promote angiogenesis and tumor growth; the Summary likewise describes this effect in RAS-driven tumor cells. The later suggestion about senescence is the citing authors’ own inference, not a finding attributed to this source. (LLM, conf=0.92)
- Supportedcites [60] Yang, 2006, Proc Natl Acad Sci U S A source
The Discussion states that RAS signals to stromal cells through Gro-1, inducing senescence and promoting tumor growth or malignant transformation. The paper’s opening summary also reports that Gro-1-induced senescent fibroblasts promote tumor growth, supporting the proposed cell-nonautonomous effect. Page numbers are not provided in our copy. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [61] Akhurst, 2001, Trends Cell Biol source
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Our results showed that human tumor cells very likely undergo senescence in response to DNA damaging chemotherapy in vivo, as reported for mice [ 49 ].”
What the sources say
- Supportedcites [49] Schmitt, 2002, Cell source
The citation is attached to “as reported for mice,” not to the citing authors’ finding about human tumor cells. The cited paper’s Discussion reports chemotherapy-induced senescence in vivo in a murine lymphoma model; it does not itself establish the human finding. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
89 more claims · 3 with their cited sources checked
Create a free account to see all 149 claims and every source verdict.
- Probably not a substantial claim. 18
- It may state two separate claims as one. 41
- Borderline: one of the tests for a substantial claim is unclear. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“the effects of the senescent fibroblasts were due primarily to their secretion of matrix metalloproteinases (MMPs), which are prominent SASP components (32, 94).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Senescent cells are metabolically active and can acquire a pro-inflammatory, tissue-destructive, pro-apoptotic senescence-associated secretory phenotype (SASP) [26]”
From Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease (2019) · cites this paper as [26]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“although it was robustly induced 7–10 days after cultured MEFs were stimulated to senesce by IR (Coppé et al., 2008)”
From An Essential Role for Senescent Cells in Optimal Wound Healing through Secretion of PDGF-AA (2014) · cites this paper as Coppé et al., 2008
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The SASP is primarily a property of cells that senesce owing to, or accompanied by, genomic damage or epigenomic perturbation.”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Many types of cytotoxic chemotherapies are severe DNA-damaging agents that can induce senescence in both tumor cells and surrounding normal cells (31–34).”
From Aging, Cellular Senescence, and Cancer (2013) · cites this paper as [32]
Experimental — accuracy not yet measured
80 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
A biomarker that identifies senescent human cells in culture and in aging skin in vivo.
Dimri, G. P., Lee, X., Basile, G., Acosta, M., Scott, G., Roskelley, C., Medrano, E. E., Linskens, M., Rubelj, I., & Pereira-Smith, O. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.20.9363 · Cited by 7,477
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Tannock, I. F., de Wit, R., Berry, W. R., Horti, J., Pluzanska, A., Chi, K. N., Oudard, S., Théodore, C., James, N. D., Turesson, I., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040720 · Cited by 5,735 · cited 5×
“We thank R. Driver for support with the array experiments, J. Gray and R. Neve for discussions, cells, and use of Cellomix; A. Huang for help with the microdissection and PCR; A. Zielinski and J. Allison for technical help; T. Beer, M. Garzotto, C. Higano, L. True, R. Vessella, and the University of Washington Medical…”
BackgroundMethodInfluentialOncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218 · cited 1×
“prototype [56], induce senescence in part by indirectly”
BackgroundCellular senescence: when bad things happen to good cells
Campisi, J., & d'Adda di Fagagna, F. (2007) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2233 · Cited by 4,441 · cited 1×
“Several lines of evidence indicate that cellular senescence is a potent tumor-suppressive mechanism [4,9,10].”
BackgroundSelf-citationPleiotropy, natural selection, and the evolution of senescence.
Williams, G. C. (1957) · Evolution · doi:10.1111/j.1558-5646.1957.tb02911.x · Cited by 4,279 · cited 1×
“It is now recognized that aging is a consequence of the declining force of natural selection with age [26,70].”
BackgroundDNA damage response as a candidate anti-cancer barrier in early human tumorigenesis
Bartkova, J., Hořejší, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Guldberg, P., Sehested, M., Nesland, J. M., Lukas, C., et al. (2005) · Nature · doi:10.1038/nature03482 · Cited by 2,688 · cited 1×
“Moreover, human cells that bypass oncogene-induced senescence [58], as well as cells in some human premalignant lesions [73,74], show signs of a persistently activated DDR.”
BackgroundSenescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas
Xue, W., Zender, L., Miething, C., Dickins, R. A., Hernando, E., Krizhanovsky, V., Cordon-Cardo, C., & Lowe, S. W. (2007) · Nature · doi:10.1038/nature05529 · Cited by 2,473 · cited 1×
“Recent findings show that tumors induced to senesce in mice gradually regress [21,22], owing perhaps to infiltration by cells of the innate immune system [22].”
BackgroundSenescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors
Campisi, J. (2005) · Cell · doi:10.1016/j.cell.2005.02.003 · Cited by 2,379
Research works printed but not linked: 80
- Hanahan, 2000, Cell, 100, 57
- Bissell, 2001, Nature Rev Cancer, 1, 46
- Coussens, 2002, Nature, 420, 860
- Campisi, 2007, Nature Rev Molec Cell Biol, 8, 729
- Dimri, 2005, Cancer Cell, 7, 505
- Ben-Porath, 2004, J Clin Invest, 113, 8
- Chau, 2003, Nature Rev Cancer, 3, 130
- Bargonetti, 2002, Curr Opin Oncol, 14, 86
- Braig, 2006, Cancer Res, 66, 2881
- Campisi, 2003, Nature Rev Canc, 3, 339
- Wright, 2001, Curr Opin Genet Dev, 11, 98
- Collins, 2003, Aging Cell, 2, 145
- Lowe, 2003, Curr Opin Genet Dev, 13, 77
- Ohtani, 2004, J Med Invest, 51, 146
- Gil, 2006, Nature Rev Molec Cell Biol, 7, 667
- Collado, 2005, Nature, 436, 642
- Chen, 2005, Nature, 436, 725
- Michaloglou, 2005, Nature, 436, 720
- Braig, 2005, Nature, 436, 660
- Shay, 2004, Oncogene, 23, 2919
- Ventura, 2007, Nature, 445, 661
- Xue, 2007, Nature, 445, 656
- Donehower, 2002, J Cell Physiol, 192, 23
- Faragher, 2000, Biochem Soc Trans, 28, 221
- Kortlever, 2006, Cell Cycle, 5, 2697
- Kirkwood, 2000, Nature, 408, 233
- Campisi, 2005, Cell, 120, 1
- Price, 2002, Aging Cell, 1, 57
- Vasile, 2001, FASEB J, 15, 458
- Matthews, 2006, Circ Res, 99, 156
- Maier, 2004, Genes Dev, 18, 306
- Tyner, 2002, Nature, 415, 45
- Zhang, 2003, Proc Natl Acad Sci U S A, 100, 3251
- Chang, 2002, Proc Natl Acad Sci U S A, 99, 389
- Bavik, 2006, Cancer Res, 66, 794
- Mason, 2004, Oncogene, 23, 9238
- Wajapeyee, 2008, Cell, 132, 363
- Kortlever, 2006, Nat Cell Biol, 8, 877
- Parrinello, 2005, J Cell Sci, 118, 485
- Kuilman, 2008, Cell, 133, 1019
- Acosta, 2008, Cell, 133, 1006
- Krtolica, 2001, Proc Natl Acad Sci U S A, 98, 12072
- Liu, 2007, Cancer Res, 67, 3117
- Parrinello, 2003, Nat Cell Biol, 5, 741
- Hayward, 1995, In Vitro Cell Dev Biol Anim, 31, 14
- Bello, 1997, Carcinogenesis, 18, 1215
- Kaighn, 1979, Invest Urol, 17, 16
- Chang, 1999, Oncogene, 18, 4808
- Schmitt, 2002, Cell, 109, 335
- Tannock, 2004, N Engl J Med, 351, 1502
- Cowin, 2005, Curr Opin Cell Biol, 17, 499
- Kokkinos, 2007, Cells Tissues Organs, 185, 191
- Dhawan, 2005, J Clin Invest, 115, 1765
- Yuan, 2005, Front Biosci, 10, 853
- Badache, 2001, Cancer Res, 61, 383
- Serrano, 1997, Cell, 88, 593
- Di Micco, 2006, Nature, 444, 638
- Mallette, 2007, Genes Dev, 21, 43
- Ancrile, 2007, Genes Dev, 21, 1714
- Yang, 2006, Proc Natl Acad Sci U S A, 103, 16472
- Akhurst, 2001, Trends Cell Biol, 11, 44
- Beausejour, 2003, EMBO J, 22, 4212
- Ossovskaya, 1996, Proc Natl Acad Sci U S A, 93, 10309
- Mantovani, 2006, Nature Rev Immunol, 6, 907
- Jeyapalan, 2007, Mech Ageing Dev, 128, 36
- Dimri, 1995, Proc Natl Acad Sci U S A, 92, 9363
- Paradis, 2001, Hum Pathol, 32, 327
- Melk, 2003, Kidney Int, 63, 2134
- Bruunsgaard, 2001, Curr Opin Hematol, 8, 131
- Williams, 1957, Evolution, 11, 398
- Roberts, 2006, Eur Spine J, 15, 312
- Herbig, 2006, Science, 311, 1257
- Bartkova, 2005, Nature, 434, 864
- Gorgoulis, 2005, Nature, 434, 907
- Kiaris, 2005, Cancer Res, 65, 1627
- Hill, 2005, Cell, 123, 1001
- Coppe, 2006, J Biol Chem, 281, 29568
- Kaminker, 2005, J Cell Sci, 118, 1321
- Kim, 2004, J Biol Chem, 279, 43799
- Krtolica, 2002, Cytometry, 49, 73
Cited by
Items 1,001–1,100 of 4,275
Regulation of Mitophagy by Sirtuin Family Proteins: A Vital Role in Aging and Age-Related Diseases
Wan, W., Hua, F., Fang, P., Li, C., Deng, F., Chen, S., Ying, J., & Wang, X. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.845330 · Cited by 74
“Although there are some differences in SASP between different tissues and aging models, the core components of SASP are mainly pro-inflammatory interleukin6 (IL-6), CXC chemokine ligand 8 (CXCL8) and monocyte chemoattractant protein 1 (MCP1) (Coppe et al., 2008).”
BackgroundIrradiation induces glioblastoma cell senescence and senescence-associated secretory phenotype
Jeon, H.-Y., Kim, J.-K., Ham, S. W., Oh, S.-Y., Kim, J., Park, J.-B., Lee, J.-Y., Kim, S.-C., & Kim, H. (2016) · Tumor Biology · doi:10.1007/s13277-015-4439-2 · Cited by 73
Enhanced Molecular Aging in Late-Life Depression: the Senescent-Associated Secretory Phenotype
Diniz, B. S., Reynolds, C. F., Sibille, E., Lin, C.-W., Tseng, G., Lotrich, F., Aizenstein, H. J., & Butters, M. A. (2017) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2016.08.018 · Cited by 73
Gong, W., Luo, C., Peng, F., Xiao, J., Zeng, Y., Yin, B., Chen, X., Li, S., He, X., Liu, Y., et al. (2021) · Clinical Science · doi:10.1042/cs20210447 · Cited by 76
Senescent macrophages in the human adipose tissue as a source of inflammaging
Matacchione, G., Perugini, J., Di Mercurio, E., Sabbatinelli, J., Prattichizzo, F., Senzacqua, M., Storci, G., Dani, C., Lezoche, G., Guerrieri, M., et al. (2022) · GeroScience · doi:10.1007/s11357-022-00536-0 · Cited by 73
“Since we recently have demonstrated a direct link between hyperglycemia and the senescent-associated secretory phenotype (SASP) in endothelial cells and macrophages [10], in this study, we aimed to characterize the senescence status acquired by macrophages in high-glucose milieu, and how it can be modulated by adipocy…”
BackgroundInfluentialAging, Cell Senescence, the Pathogenesis and Targeted Therapies of Osteoarthritis
Zhang, X., He, S., Liang, X., Li, W., Li, T.-F., & Li, D. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.728100 · Cited by 88
Uryga, A. K., Grootaert, M. O. J., Garrido, A. M., Oc, S., Foote, K., Chappell, J., Finigan, A., Rossiello, F., d’Adda di Fagagna, F., Aravani, D., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02123-z · Cited by 73
Cellular Plasticity: A Route to Senescence Exit and Tumorigenesis
De Blander, H., Morel, A.-P., Senaratne, A. P., Ouzounova, M., & Puisieux, A. (2021) · Cancers · doi:10.3390/cancers13184561 · Cited by 72
“The paracrine action of SASP factors can indeed be pro-tumoral via its effect on EMT, given the widely demonstrated role of EMT in invasion and metastatic dissemination [99,122,170,171] (Figure 3).”
BackgroundAngiogenesis, Cancer, and Vascular Aging
Moriya, J., & Minamino, T. (2017) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2017.00065 · Cited by 73
“In addition to the decline of replicative capacity, cellular senescence leads to increased expression of inflammatory cytokines and decreased production of NO by the vascular endothelium (87, 88).”
BackgroundRedox Control of the Senescence Regulator Interleukin-1α and the Secretory Phenotype
McCarthy, D. A., Clark, R. R., Bartling, T. R., Trebak, M., & Melendez, J. A. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.493841 · Cited by 73
“Oxidative Stress and Ca(2) Regulate the SASP—SA IL-1 has been reported to functionally act as an initiator of the SASP (1, 6, 20), which is characterized by high levels of inflammatory cytokines, such as IL-6 and IL-8.”
BackgroundSelenium Compounds Activate Early Barriers of Tumorigenesis
Wu, M., Kang, M. M., Schoene, N. W., & Cheng, W. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.088781 · Cited by 80
Anti‐inflammatory treatment rescues memory deficits during aging in nfkb1−/− mice
Fielder, E., Tweedy, C., Wilson, C., Oakley, F., LeBeau, F. E. N., Passos, J. F., Mann, D. A., von Zglinicki, T., & Jurk, D. (2020) · Aging Cell · doi:10.1111/acel.13188 · Cited by 71
“Impaired adult neurogenesis associated with short-term memory defects in NF-κB p50-deficient mice.”
BackgroundInfluentialThe ER stress regulator Bip mediates cadmium-induced autophagy and neuronal senescence
Wang, T., Yuan, Y., Zou, H., Yang, J., Zhao, S., Ma, Y., Wang, Y., Bian, J., Liu, X., Gu, J., et al. (2016) · Scientific Reports · doi:10.1038/srep38091 · Cited by 75
“These studies demonstrate that a hallmark of physiologically senescent cells is a massively increase in the secretions of multiple proinflammatory proteins, including IL-6, IL-8 (CXCL8) and other chemokines and cytokines 22–24 .”
Narzt, M.-S., Pils, V., Kremslehner, C., Nagelreiter, I.-M., Schosserer, M., Bessonova, E., Bayer, A., Reifschneider, R., Terlecki-Zaniewicz, L., Waidhofer-Söllner, P., et al. (2021) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.11.020 · Cited by 73
ATM regulation of IL-8 links oxidative stress to cancer cell migration and invasion
Chen, W.-T., Ebelt, N. D., Stracker, T. H., Xhemalce, B., Van Den Berg, C. L., & Miller, K. M. (2015) · eLife · doi:10.7554/elife.07270 · Cited by 73
“Senescent cells are thought to promote tumor progression in the microenvironment through paracrine signaling by secreted pro-inflammatory factors including cytokines (Coppe et al., 2008, 2010).”
BackgroundMolecular Pathways: Involving Microenvironment Damage Responses in Cancer Therapy Resistance
Sun, Y., & Nelson, P. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0768 · Cited by 73
Self-citationCavinato, M., Koziel, R., Romani, N., Weinmüllner, R., Jenewein, B., Hermann, M., Dubrac, S., Ratzinger, G., Grillari, J., Schmuth, M., et al. (2016) · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences · doi:10.1093/gerona/glw150 · Cited by 73
The intensities of canonical senescence biomarkers integrate the duration of cell-cycle withdrawal
Ashraf, H. M., Fernandez, B., & Spencer, S. L. (2023) · Nature Communications · doi:10.1038/s41467-023-40132-0 · Cited by 72
“Furthermore, we performed the same analysis on cells stained for IL6, the most commonly upregulated SASP factor (21,22), by mRNA fluorescence in situ hybridization (FISH), and observed a similar trend (Fig.”
EGF promotes mammalian cell growth by suppressing cellular senescence
Alexander, P. B., Yuan, L., Yang, P., Sun, T., Chen, R., Xiang, H., Chen, J., Wu, H., Radiloff, D. R., & Wang, X. (2014) · Cell Research · doi:10.1038/cr.2014.141 · Cited by 77
Cellular senescence in age-related disorders
Kaur, J., & Farr, J. N. (2020) · Translational research · doi:10.1016/j.trsl.2020.06.007 · Cited by 84
Acklin, S., Zhang, M., Du, W., Zhao, X., Plotkin, M., Chang, J., Campisi, J., Zhou, D., & Xia, F. (2020) · Scientific Reports · doi:10.1038/s41598-020-71042-6 · Cited by 73
Self-citationModulation of the Senescence-Associated Inflammatory Phenotype in Human Fibroblasts by Olive Phenols
Menicacci, B., Cipriani, C., Margheri, F., Mocali, A., & Giovannelli, L. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112275 · Cited by 72
“In particular, senescent cells are characterized by a strong increase in the secretion of growth factors, inflammatory cytokines, and proteolytic enzymes, termed the “senescence-associated secretory phenotype” (SASP), that has been thoroughly described in cultured fibroblasts [2].”
BackgroundRibeiro, R., Macedo, J. C., Costa, M., Ustiyan, V., Shindyapina, A. V., Tyshkovskiy, A., Gomes, R. N., Castro, J. P., Kalin, T. V., Vasques-Nóvoa, F., et al. (2022) · Nature Aging · doi:10.1038/s43587-022-00209-9 · Cited by 60
Yu, S., Wang, X., Geng, P., Tang, X., Xiang, L., Lu, X., Li, J., Ruan, Z., Chen, J., Xie, G., et al. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12405 · Cited by 72
Li, G., Luna, C., Qiu, J., Epstein, D. L., & Gonzalez, P. (2010) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.09-4874 · Cited by 72
Yun, J., Hansen, S., Morris, O., Madden, D. T., Libeu, C. P., Kumar, A. J., Wehrfritz, C., Nile, A. H., Zhang, Y., Zhou, L., et al. (2023) · Nature Communications · doi:10.1038/s41467-022-35487-9 · Cited by 88
Self-citationLiakou, E., Mavrogonatou, E., Pratsinis, H., Rizou, S., Evangelou, K., Panagiotou, P. N., Karamanos, N. K., Gorgoulis, V. G., & Kletsas, D. (2016) · Aging · doi:10.18632/aging.100989 · Cited by 72
“Senescent fibroblasts secrete a large number of catabolic and inflammatory mediators that may affect local tissue homeostasis and even promote the growth of adjacent tumor cells [37].”
InfluentialCellular senescence: a hitchhiker’s guide
Aravinthan, A. (2015) · Human Cell · doi:10.1007/s13577-015-0110-x · Cited by 72
“These secreted factors are involved in the induction and maintenance of senescence, alteration of the microenvironment, chemo-attraction of immune cells and tumourigenesis [126, 128].”
BackgroundOhtani, N. (2014) · Seminars in Immunopathology · doi:10.1007/s00281-014-0457-1 · Cited by 79
“to as the senescence-associated secretome), is induced by DNA damage and can be beneficial or deleterious, depending on the biological context [35, 39].”
BackgroundKaneda, A., Fujita, T., Anai, M., Yamamoto, S., Nagae, G., Morikawa, M., Tsuji, S., Oshima, M., Miyazono, K., & Aburatani, H. (2011) · PLoS Genetics · doi:10.1371/journal.pgen.1002359 · Cited by 72
“. Although the roles of RB and p53 signaling pathways in senescence are undisputed, it has become clear that other factors are also involved. Expression of secreted factors, or “senescence-messaging secretome”, has been proposed as an example of such mechanisms”
BackgroundMiyata, K., Imai, Y., Hori, S., Nishio, M., Loo, T. M., Okada, R., Yang, L., Nakadai, T., Maruyama, R., Fujii, R., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2025647118 · Cited by 74
“D ) (25).”
Chromosomal instability-induced senescence potentiates cell non-autonomous tumourigenic effects
He, Q., Au, B., Kulkarni, M., Shen, Y., Lim, K. J., Maimaiti, J., Wong, C. K., Luijten, M. N. H., Chong, H. C., Lim, E. H., et al. (2018) · Oncogenesis · doi:10.1038/s41389-018-0072-4 · Cited by 68
Lessons from senescence: Chromatin maintenance in non-proliferating cells
Rai, T. S., & Adams, P. D. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.07.014 · Cited by 71
Transcriptional repression of DNA repair genes is a hallmark and a cause of cellular senescence
Collin, G., Huna, A., Warnier, M., Flaman, J.-M., & Bernard, D. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0300-z · Cited by 71
Obesity and Cancer: A Gut Microbial Connection
Ohtani, N., Yoshimoto, S., & Hara, E. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3501 · Cited by 71
Giroud, J., Bouriez, I., Paulus, H., Pourtier, A., Debacq-Chainiaux, F., & Pluquet, O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241310788 · Cited by 73
“CXCL1-2-3 Human fibroblasts (IMR90, HCA2) Prostate epithelial cells (PrECs) Irradiation-induced senescence Replicative Senescence Antibodies array [9,29]”
BackgroundInfluentialModulation of fracture healing by the transient accumulation of senescent cells
Saul, D., Monroe, D. G., Rowsey, J. L., Kosinsky, R. L., Vos, S. J., Doolittle, M. L., Farr, J. N., & Khosla, S. (2021) · eLife · doi:10.7554/elife.69958 · Cited by 71
Therapeutic Potential of Senolytics in Cardiovascular Disease
Dookun, E., Passos, J. F., Arthur, H. M., & Richardson, G. D. (2022) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-020-07075-w · Cited by 69
Inflammation: a matter of immune cell life and death
Bender, E. C., Tareq, H. S., & Suggs, L. J. (2025) · npj Biomedical Innovations. · doi:10.1038/s44385-025-00010-4 · Cited by 97
Mária, J., & Ingrid, Ž. (2017) · Food & Function · doi:10.1039/c7fo00161d · Cited by 71
Cevenini, E., Bellavista, E., Tieri, P., Castellani, G., Lescai, F., Francesconi, M., Mishto, M., Santoro, A., Valensin, S., Salvioli, S., et al. (2010) · Current Pharmaceutical Design · doi:10.2174/138161210790883660 · Cited by 71
Hardeland, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158296 · Cited by 71
“Moreover, it should be remembered that astrocytes can secrete cytokines, chemokines, and other factors in the course of developing a senescence-associated secretory phenotype (SASP) [2,87], a process of relevance to lowgrade neuroinflammation in neurodegenerative diseases and inflammaging [2,88,89] and is part of the…”
BackgroundMancini, Ö. K., Lora, M., Shum‐Tim, D., Nadeau, S., Rodier, F., & Colmegna, I. (2017) · Stem Cells Translational Medicine · doi:10.1002/sctm.16-0221 · Cited by 96
Self-citationAPE1 deficiency promotes cellular senescence and premature aging features
Li, M., Yang, X., Lu, X., Dai, N., Zhang, S., Cheng, Y., Zhang, L., Yang, Y., Liu, Y., Yang, Z., et al. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky326 · Cited by 73
“In particular, most of the SASP-related secretion factors, including interleukins 6 and 8, matrix metalloproteinases, pro-neurogenic factors and pro-angiogenic factors, have been shown to promote the proliferation of precancerous and cancerous cells (51), enhance invasion, and induce an epithelial to mesenchymal trans…”
BackgroundGolomb, L., Sagiv, A., Pateras, I. S., Maly, A., Krizhanovsky, V, Gorgoulis, V. G., Oren, M., & Ben-Yehuda, A. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2015.21 · Cited by 71
“GSEA analysis of mRNA expression data (see Figure 1d) confirmed enrichment for SASP genes in old skin (Figure 2e), based on a previously described set of proteins secreted by cultured human senescent cells.(36,37) Expression of four SASP genes, CCR1, SPP1, IL6 and IL1β, was also validated by reverse transcriptase quan…”
BackgroundRole of the microbiome in non-gastrointestinal cancers
Pevsner-Fischer, M., Tuganbaev, T., Meijer, M., Zhang, S.-H., Zeng, Z.-R., Chen, M.-H., & Elinav, E. (2016) · World Journal of Clinical Oncology · doi:10.5306/wjco.v7.i2.200 · Cited by 70
Time-dependent replicative senescence vs. disturbed flow-induced pre-mature aging in atherosclerosis
Dominic, A., Banerjee, P., Hamilton, D. J., Le, N., & Abe, J. (2020) · Redox Biology · doi:10.1016/j.redox.2020.101614 · Cited by 77
Paland, N., Kamer, I., Kogan-Sakin, I., Madar, S., Goldfinger, N., & Rotter, V. (2009) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-09-0073 · Cited by 82
“Recently, it was shown that senescence leads to a senescence-associated secretory phenotype, including the enhanced secretion of IL-6 and IL-8 (56).”
BackgroundCherry, C., Andorko, J. I., Krishnan, K., Mejías, J. C., Nguyen, H. H., Stivers, K. B., Gray-Gaillard, E. F., Ruta, A., Han, J., Hamada, N., et al. (2023) · GeroScience · doi:10.1007/s11357-023-00785-7 · Cited by 66
DOT1L modulates the senescence-associated secretory phenotype through epigenetic regulation of IL1A
Leon, K. E., Buj, R., Lesko, E., Dahl, E. S., Chen, C.-W., Tangudu, N. K., Imamura-Kawasawa, Y., Kossenkov, A. V., Hobbs, R. P., & Aird, K. M. (2021) · Journal of Cell Biology · doi:10.1083/jcb.202008101 · Cited by 70
“While the SASP may enhance immune cell recruitment and clearance of senescent cells, it also has detrimental side effects, resulting in chronic inflammation that contributes to tumorigenesis and chemoresistance (Copp´e et al., 2008).”
InfluentialPro- and anti-tumorigenic functions of the senescence-associated secretory phenotype
Lau, L., & David, G. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1565658 · Cited by 70
“tering and reduced cell-cell adhesions, another mesenchymal phenotype [34].”
BackgroundInfluentialBitar, M. S. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20030673 · Cited by 78
“Similarly, these cells also showed a feature of the senescence-associated secretory phenotype (SASP) as typified by the elevation in mRNA or protein levels of proinflammatory cytokines (TNF-α, IL-6 and IL-8), prothrombotic (PAI-1) and insulin-like growth factor binding protein 5 (IGF-BP5) (Figure 4B–”
ResultInfluentialCellular senescence: a view throughout organismal life
von Kobbe, C. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2879-8 · Cited by 76
Clinical guidelines for primary sclerosing cholangitis 2017
Isayama, H., Tazuma, S., Kokudo, N., Tanaka, A., Tsuyuguchi, T., Nakazawa, T., Notohara, K., Mizuno, S., Akamatsu, N., Serikawa, M., et al. (2018) · Journal of Gastroenterology · doi:10.1007/s00535-018-1484-9 · Cited by 73
Targeting senescent cells: possible implications for delaying skin aging: a mini-review
Velarde, M. C., & Demaria, M. (2016) · Gerontology · doi:10.1159/000444877 · Cited by 69
Parallel pathways in RAF-induced senescence and conditions for its reversion
Jeanblanc, M., Ragu, S., Gey, C., Contrepois, K., Courbeyrette, R., Thuret, J., & Mann, C. (2011) · Oncogene · doi:10.1038/onc.2011.481 · Cited by 79
Pyroptotic and non‐pyroptotic effector functions of caspase‐11
Khweek, A. A., & Amer, A. O. (2020) · Immunological Reviews · doi:10.1111/imr.12910 · Cited by 72
Neuregulin-1 attenuates stress-induced vascular senescence
Shakeri, H., Gevaert, A. B., Schrijvers, D. M., Meyer, G. R. Y. D., Keulenaer, G. W. D., Guns, P., Lemmens, K., & Segers, V. F. M. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy059 · Cited by 73
“bouring microenvironment by a phenomenon known as the senescenceassociated secretory phenotype (SASP).(4,5) Cellular senescence and SASP play an important role in cardiovascular ageing and disease.”
BackgroundVarela-Eirín, M., & Demaria, M. (2022) · Current Biology · doi:10.1016/j.cub.2022.04.003 · Cited by 81
The Regulation of Cellular Functions by the p53 Protein: Cellular Senescence
Tonnessen-Murray, C. A., Lozano, G., & Jackson, J. G. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a026112 · Cited by 70
“Further, p53-mediated senescence suppresses tumors in mice with deprotected telomeres (Cosme-Blanco et al. 2007; Feldser and Greider 2007).”
BackgroundThe senescence journey in cancer immunoediting
Zingoni, A., Antonangeli, F., Sozzani, S., Santoni, A., Cippitelli, M., & Soriani, A. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01973-5 · Cited by 84
“The SASP components released by senescent stroma include different cytokines and chemokines (e.g. CXCL8 and CXCL3), different growth factors, including amphiregulin (AREG), and are mainly involved in inducing and accelerating disease progression via paracrine actions [37, 105, 117, 118].”
BackgroundTelomere Dysfunction and Cell Senescence in Chronic Lung Diseases: Therapeutic Potential
Adnot, S., Amsellem, V., Boyer, L., Marcos, É., Saker, M., Houssaini, A., Kebe, K., Dagouassat, M., Lipskaia, L., & Boczkowski, J. (2015) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2015.06.007 · Cited by 72
Premature aging/senescence in cancer cells facing therapy: good or bad?
Calvo, L., Ghadaouia, S., Martinez, A., & Rodier, F. (2015) · Biogerontology · doi:10.1007/s10522-015-9593-9 · Cited by 82
Self-citationRole of Senescence and Aging in SARS-CoV-2 Infection and COVID-19 Disease
Lynch, S. M., Guo, G., Gibson, D. S., Bjourson, A. J., & Singh, T. (2021) · Cells · doi:10.3390/cells10123367 · Cited by 75
Tiberi, J., Cesarini, V., Stefanelli, R., Canterini, S., Fiorenza, M. T., & Rosa, P. L. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111802 · Cited by 81
Senescence Induced by BMI1 Inhibition Is a Therapeutic Vulnerability in H3K27M-Mutant DIPG
Balakrishnan, I., Danis, E., Pierce, A., Madhavan, K., Wang, D., Dahl, N., Sanford, B., Birks, D. K., Davidson, N., Metselaar, D. S., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108286 · Cited by 69
“Senescent cells are not quiescent but rather metabolically active cells that secrete multiple pro-inflammatory cytokines and chemokines, which can promote malignant phenotypes (Coppé et al., 2008; Freund et al., 2010; Muñoz-Espı́n and Serrano, 2014).”
BackgroundCao, Y., Yao, M., Wu, Y., Ma, N., Liu, H., & Zhang, B. (2020) · Translational Oncology · doi:10.1016/j.tranon.2020.100783 · Cited by 72
The Spectrum of Fundamental Basic Science Discoveries Contributing to Organismal Aging
Farr, J. N., & Almeida, M. (2018) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3564 · Cited by 69
Basisty, N., Kale, A., Patel, S., Campisi, J., & Schilling, B. (2020) · Expert Review of Proteomics · doi:10.1080/14789450.2020.1766976 · Cited by 69
“For example, an early study applied cytokine antibody arrays to identify a few dozen SASP proteins, many of which were induced by multiple stimuli, such as replicative exhaustion, ionizing radiation (10 Gy) and RASoncogene expression [20].”
BackgroundSelf-citationConnecting the Dots: From DNA Damage and Repair to Aging
Pan, M., Li, K., Lin, S., & Hung, W.-C. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050685 · Cited by 79
“One well-known characteristic of senescent cells is the production of pro-inflammatory and matrix-degrading molecules, known as the senescence-associat d secretory p notype (SASP) [74,75].”
BackgroundInfluentialBonney, E. A. (2017) · American Journal of Reproductive Immunology · doi:10.1111/aji.12652 · Cited by 80
(2021) · doi:10.1038/s43587-021-00063-1 · Cited by 66
“PC3/PSC27 ML324 MIT + + + + – + – + – – + + (1) (2) (3) (4) 74.”
Self-citationRetractedThe Role of MAPK in Drug-Induced Kidney Injury
Cassidy, H., Radford, R., Slyne, J., O’Connell, S., Slattery, C., Ryan, M. P., & McMorrow, T. (2012) · Journal of Signal Transduction · doi:10.1155/2012/463617 · Cited by 73
“This organic ion transport system may allow toxic compounds to accumulate in the cells of the nephron which may otherwise not gain access to the cytosol [81].”
BackgroundCCN2 induces cellular senescence in fibroblasts
Jun, J.-I., & Lau, L. F. (2017) · Journal of Cell Communication and Signaling · doi:10.1007/s12079-016-0359-1 · Cited by 68
Sławińska, N., & Krupa, R. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020590 · Cited by 68
“The variety of secreted substances depends on cell type—for example, senescent retinal pigment epithelium (RPE) does not secrete inflammation regulating factors as opposed to senescent human fibroblasts [41].”
BackgroundInfluentialFunctional Role of Cellular Senescence in Biliary Injury
Meng, L., Quezada, M., Levine, P., Han, Y., McDaniel, K., Zhou, T., Lin, E., Glaser, S., Meng, F., Francis, H., et al. (2015) · The American Journal of Pathology · doi:10.1016/j.ajpath.2014.10.027 · Cited by 68
Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
Oo, W. M., & Hunter, D. J. (2022) · Therapeutic Advances in Musculoskeletal Disease · doi:10.1177/1759720x221090297 · Cited by 81
Markers of cellular senescence.
Carnero, A. (2013) · Methods in Molecular Biology · doi:10.1007/978-1-62703-239-1_4 · Cited by 68
Recent advances in the treatment and delivery system of diabetic retinopathy
Wang, Z., Zhang, N., Lin, P., Xing, Y., & Yang, N. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1347864 · Cited by 88
Cellular senescence is a promising target for chronic wounds: a comprehensive review
Wang, Z., & Shi, C. (2020) · Burns & Trauma · doi:10.1093/burnst/tkaa021 · Cited by 82
“Senescent cells secrete a series of SASPs that regulate the surrounding microenvironment, which directly or indirectly affects various processes of regeneration, including angiogenesis, matrix remodelling, cell plasticity and growth [42, 43, 55].”
BackgroundMalavolta, M., Pierpaoli, E., Giacconi, R., Costarelli, L., Piacenza, F., Basso, A., Cardelli, M., & Provinciali, M. (2016) · Current Drug Targets · doi:10.2174/1389450116666150907105104 · Cited by 68
To help aging populations, classify organismal senescence
Calimport, S. R. G., Bentley, B. L., Stewart, C. E., Pawelec, G., Scuteri, A., Vinciguerra, M., Slack, C., Chen, D., Harries, L. W., Marchant, G., et al. (2019) · Science · doi:10.1126/science.aay7319 · Cited by 67
Self-citationIwagami, Y., Huang, C., Olsen, M. J., Thomas, J., Jang, G., Kim, M., Lin, Q., Carlson, R. I., Wagner, C. E., Dong, X., et al. (2015) · Hepatology · doi:10.1002/hep.28411 · Cited by 73
Nguyen, P. T., Kanno, K., Phạm, Q. T., Kikuchi, Y. S., Kakimoto, M., Kobayashi, T., Otani, Y., Kishikawa, N., Miyauchi, M., Arihiro, K., et al. (2020) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-020-03374-9 · Cited by 73
Zhang, Y., Yang, B., Wang, J., Cheng, F., Shi, K., Ying, L., Wang, C., Xia, K., Huang, X., Gong, Z., et al. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/9503562 · Cited by 82
Stress granules counteract senescence by sequestration of PAI‐1
Omer, A., Patel, D. M., Lian, X. J., Sadek, J., Marco, S. D., Pause, A., Gorospe, M., & Gallouzi, I. (2018) · EMBO Reports · doi:10.15252/embr.201744722 · Cited by 71
“Mechanistically, we found that the SG-mediated inhibition of senescence correlates with their ability to recruit PAI-1, a member of the SASP and a well-known promoter of senescence [11 – 13, 69 ].”
InfluentialMurali, B., Ren, Q., Luo, X., Faget, D. V., Wang, C., Johnson, R. M., Gruosso, T., Flanagan, K. C., Fu, Y., Leahy, K., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0234 · Cited by 67
STAT3 and metabolism: How many ways to use a single molecule?
Demaria, M., Camporeale, A., & Poli, V. (2014) · International Journal of Cancer · doi:10.1002/ijc.28767 · Cited by 67
Kim, E., Rebecca, V., Fedorenko, I. V., Messina, J. L., Mathew, R., Maria-Engler, S. S., Basanta, D., Smalley, K. S. M., & Anderson, A. R. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1720 · Cited by 66
Dysregulated inflammation as a risk factor for pneumonia in the elderly.
Boyd, A. R., & Orihuela, C. J. (2011) · Europe PMC (PubMed Central) · Cited by 81
Elsallabi, O., Patruno, A., Pesce, M., Cataldi, A., Carradori, S., & Gallorini, M. (2022) · Molecules · doi:10.3390/molecules27030738 · Cited by 67
“Senescenceupregulated proinflammatory cytokines, including IL-6, IL-1β, and TNF-α, were highly expressed in microglia from aged mice [49,60,61].”
BackgroundChemokine and chemokine receptors in autoimmunity: the case of primary biliary cholangitis
Choi, J., Selmi, C., Leung, P. S. C., Kenny, T. P., Roskams, T., & Gershwin, M. E. (2016) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2016.1147956 · Cited by 67
“BECexpressed chemokines cause mononuclear cells to infiltrate into the damaged sites in PBC [69], and BEC senescence contributes to non-suppurative destructive damage in PBC by altering microenvironment in conjunction with the upregulation of senescence-associated secretory phenotype such as cytokines (IL-1 and IL-6),…”
BackgroundIncreased expression and accumulation of GDF15 in IPF extracellular matrix contribute to fibrosis
Radwańska, A., Cottage, C. T., Piras, A., Overed-Sayer, C. L., Sihlbom, C., Budida, R., Wrench, C., Connor, J., Monkley, S. J., Hazon, P., et al. (2022) · JCI Insight · doi:10.1172/jci.insight.153058 · Cited by 72
“senescence markers, such as p21 (Cdkn1a) and Ccl2 (50).”
InfluentialSohn, J. J., Schetter, A. J., Yfantis, H. G., Ridnour, L. A., Horikawa, I., Khan, M. A., Robles, A. I., Hussain, S. P., Goto, A., Bowman, E. D., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0044156 · Cited by 66
Zhang, R., Chen, H., & Liu, D. (2015) · Cell Systems · doi:10.1016/j.cels.2015.09.002 · Cited by 74
The effect of chronological age on the inflammatory response of human fibroblasts
Wolf, J., Weinberger, B., Arnold, C. R., Maier, A. B., Westendorp, R. G. J., & Grubeck-Loebenstein, B. (2012) · Experimental Gerontology · doi:10.1016/j.exger.2012.07.001 · Cited by 66
“Despite the known capacity of fibroblasts to produce cytokines, particularly during replicative senescence (Coppe et al., 2008), the effects of aging on the inflammatory response of fibroblasts to cellular stress such as viral and/or bacterial infection have only scarcely been elucidated.”
Hallmarks and Biomarkers of Skin Senescence: An Updated Review of Skin Senotherapeutics
Bulbiankova, D., Díaz‐Puertas, R., Álvarez‐Martínez, F. J., Herranz‐López, M., Barrajón‐Catalán, E., & Micol, V. (2023) · Antioxidants · doi:10.3390/antiox12020444 · Cited by 75
A CDK4/6-Dependent Epigenetic Mechanism Protects Cancer Cells from PML-induced Senescence
Acevedo, M., Vernier, M., Mignacca, L., Lessard, F., Huot, G., Moiseeva, O., Bourdeau, V., & Ferbeyre, G. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2347 · Cited by 66
“One hallmark of senescence is the upregulation of genes involved in inflammation and the immune response (29).”
BackgroundTominaga, T., Shimada, R., Okada, Y., Kawamata, T., & Kibayashi, K. (2019) · PLOS ONE · doi:10.1371/journal.pone.0213673 · Cited by 66
Oxidative DNA damage caused by inflammation may link to stress-induced non-targeted effects
Sprung, C. N., Ivashkevich, A. N., Forrester, H. B., Redon, C. E., Georgakilas, A. G., & Martin, O. A. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.09.008 · Cited by 70
“Therefore, senescent cells are also able to induce genomic instability in their neighbors by establishing a chronic inflammatory environment by secreting a senescenceassociated secretory phenotype (SASP) [128,129].”
Background
Metadata
- Authors
- Coppé, J.-P., Patil, C. K., Rodier, F., Sun, Y., Muñoz, D. P., Goldstein, J., Nelson, P. S., Desprez, P.-Y., & Campisi, J.
- Affiliations
- Lawrence Berkeley National Laboratory (US)
- Fred Hutch Cancer Center (US)
- Buck Institute for Research on Aging (US)
- Corresponding author
- Campisi, Judith
- Venue
- PLoS Biology
- Publisher
- Public Library of Science (PLoS)
- Published
- 2008-12-02
- Volume
- 6
- Issue
- 12
- Pages
- e301
- ISSN
- 1544-9173 (ISSN-L)
- 1545-7885
- PMC
- PMC2592359
- OpenAlex
- W239602587
- Cited by
- 302
- References
- 81
- Citations by year
- 2025: 16 · 2024: 29 · 2023: 30 · 2022: 38 · 2021: 49 · 2020: 26 · 2019: 15 · 2018: 12 · 2017: 16 · 2016: 16 · 2015: 11 · 2014: 8 · 2013: 4 · 2012: 9
- FWCI
- 5.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS Biology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of North Texas Digital Library (University of North Texas) (submittedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship (California Digital Library) (submittedVersion)
- Figshare (submittedVersion, cc-by)
- Lawrence Berkeley National Laboratory
- Funders
- Larry L. Hillblom Foundation
- University of Washington
- National Institutes of Health (AG09909, AG017242, CA126540, AG000266)
- National Institute on Aging (R56AG009909, AG017242, AG-09909, R37AG009909, AG000266, P01AG017242, T32AG000266)
- National Cancer Institute (CA126540, CA 97186, U54CA126540, P50CA097186)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Aging › Genetics, Aging, and Longevity in Model Organisms
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- senescence-associated secretory phenotype, cellular senescence, genotoxic stress, oncogenic Ras, p53 tumor suppressor, paracrine signaling, interleukin-6, interleukin-8, epithelial-mesenchymal transition, tumor invasion, prostate cancer chemotherapy, tissue microenvironment, age-related cancer
- MeSH terms
- Adult, Aging, Antineoplastic Agents, Cells, Cultured, Epithelial Cells, Fibroblasts, Humans, Infant, Newborn, Male, Neoplasm Invasiveness, Neoplasms, Phenotype, Prostatic Neoplasms, Genes, ras, Interleukin-6, Tumor Suppressor Protein p53, Interleukin-8, Cellular Senescence, Cell Line, Tumor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-29, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-29 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.